Congratulations to Dr Giusy Di Conza and collaborators for their publication Cancer Research Communications on preclinical testing of a novel PI3Kdelta inhibitor IOA-244/Roginolisib in solid tumors @MathiasWenes Denis Migliorini Francesco Bertoni iOnctura Université de Genève SIB Cambridge University USI University

These were amazing 4days at Summer Business School at Campus Biotech Innovation Park organized by iOnctura . Learning how to transit from idea to a start up . Thanks to PIPgen for this opportunity. PS. And a nice end of the week with Half-Marathon in Geneva.

Please to have been featured in drug hunter's drug of the month list! 👏😀 drughunter.com/molecules-of-t…

Our latest translational research of IOA-289 has been published in ESMO - Eur. Oncology journal Immuno-Oncology and Technology 👏 esmoiotech.org/article/S2590-…

The iOnctura team is out and about this month, talking about all the great research we arae generating, building on the promise of #roginolisib in solid tumors and hematological malignanies. We will be at ASCO, EHA, EACR and ICML. If you want to meet with us, please reach out.

We are at European Hematology Association (EHA)! Look out for our CMO, Michael Lahn, if you would like to hear more about how we are revolutionizing the PI3Kd landscape with our next-generation, allosteric modulator #roginolisib.

Are you at EACR? Come and visit us at our poster tomorrow to learn more about the combination potential of our PI3Kd program, roginolisib....

The PI3Kδ space is being revived, want to know how? Join Giusy Di Conza, Head of Research at iOnctura , at #ELRIGDD23 to learn how roginolisib is paving the way for the safe targeting of PI3Kδ in solid and haematologic tumours 🎯 🎫Register FREE: rb.gy/db135

New research published by us highlighting the potential of an autotaxin TGFb inhibition strategy in overcoming resistance in pancreatic cancer 👏

New data to be presented at ASH in December... Come and visit our posters 👏

🗞 BREAKING NEWS! 🗞 We have been granted ODD by the US FDA for our autotaxin inhibitor cambritaxestat (previously known as IOA-289) for the treatment of pancreatic cancer 👏 This is an exciting step to accelerate progress through the clinic 🏃‍♀️

Pleased to announce we have been awarded funding from the KWF Cancer Society to further the development of IOA-289 for fibrotic tumors 👏

Will you be at ASCO this weekend? We will be; we are sharing updated results from our Phase I/II DIONE-01 study tomorrow afternoon.

Congratulations iOnctura ! This new funding will advance treatments for neglected cancers. Thrilled to support your journey with Merck and Syncona! More milestones ahead! tinyurl.com/26kejwy4 Schroders VI Partners iOnctura #OnMyHorizon

🗞 Breaking News! 🗞 We are thrilled to announce we have successfully closed our 80M Euro Series B financing round 📣 to accelerate #roginolisib for #uvealmelanoma and other other indications. Watch this space as we kick off a nmber of randomized Phase II studies later in 2024.

.iOnctura aiming to reopen PI3K-delta space, adds €80M in series B bioworld.com/articles/709851 #biotech #pharma

Introducing iOnctura 2.0 🚀 To develop high impact, low disruption therapies that extend healthspan. Our mission is a simple, but hugely powerful one. We’re excited to present a completely overhauled brand — a brand that truly reflects this mission.

We have expanded #roginolisib's clinical trial program to NSCLC 💊 Via new partnerships with GSK and ETOP IBCSG Partners Foundation, the study will investigate #dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to checkpoint inhibitor therapy

And this is the result of the collaboration between CSVPA artists and PIPgen ESRs! Thanks Sienna for this amazing reel. If you want to see the final artworks com an visit the exhibition at WESTHub. MOre info here: linktr.ee/pipgen

Today we are providing a clinical update on #roginolisib: 👉 Clinical activity and long-term safety for our unique allosteric modulator of PI3Kδ 👉 Patients with uveal melanoma doubled OS compared to historical controls 👉 Site activation ongoing for PII